It is easy to be cynical about announcements of drugs that claim to slow the progress of Alzheimer’s disease, the most common form of . Lecanemab, however, may be the real deal. Read more: https://www.economist.com/science-and-technology/2022/11/30/a-drug-for-alzheimers-disease-that-seems-to-work
Great Bay Bio, a Hong Kong-based high-tech enterprise dedicated to applying artificial intelligence and other technologies in CMC bioprocessing, completed a near USD10M Series A funding. The round was led by Proxima Ventures with participation from many new and existing institutional investors…. Continue Reading →
Chinese upstart companies and IT goliaths hope to turn countrys artificial intelligence prowess into world-leading drug innovation. Do they have an edge over Western players? Chinese researchers are abuzz about the potential of artificial intelligence (AI) in drug design and… Continue Reading →
AstraZeneca has partnered with Hong Kong Science and Technology Parks (HKSTP) to set up an incubation program for biomedical startups. The program is designed to attract and support local and overseas startups working to improve the treatment and diagnosis of… Continue Reading →
Read more: https://bit.ly/379Ks6N
Zhaoke Ophthalmology Pharmaceutical (ZKO), an indirect subsidiary of Hong Kong-listed Lee’s Pharmaceutical Holdings Limited, has garnered as much as $145 million in its Series B round co-led by Hillhouse Capital’s Hillhouse COFL and TPG Asia, per a filing with the… Continue Reading →
李小加認為，中國面對人口老化與醫療成本上漲，需透過生科企業尋找解決方法。（信報資料圖片） Read more: https://bit.ly/3i6eDP0
要有效對應疫情，進行病毒檢測可說是重要的一環。一直以來檢測成本貴而且需時，最近理大得到政府撥款$1,800 萬，針對今次疫情作研究，當中得到超過$270 萬資助的項目是開發手提檢測儀及病毒測試劑，加快檢測流程並降低門 Read more: https://bit.ly/3gkcg9W
Professor Kelvin Tsoi is an Epidemiologist specialized in Digital Health. Read more: https://bit.ly/2YHh3fU
© 2024 尹思哲 — Powered by WordPress
Theme by Anders Noren — Up ↑